RU2017123551A3 - - Google Patents

Download PDF

Info

Publication number
RU2017123551A3
RU2017123551A3 RU2017123551A RU2017123551A RU2017123551A3 RU 2017123551 A3 RU2017123551 A3 RU 2017123551A3 RU 2017123551 A RU2017123551 A RU 2017123551A RU 2017123551 A RU2017123551 A RU 2017123551A RU 2017123551 A3 RU2017123551 A3 RU 2017123551A3
Authority
RU
Russia
Application number
RU2017123551A
Other languages
Russian (ru)
Other versions
RU2762359C2 (ru
RU2017123551A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017123551A publication Critical patent/RU2017123551A/ru
Publication of RU2017123551A3 publication Critical patent/RU2017123551A3/ru
Application granted granted Critical
Publication of RU2762359C2 publication Critical patent/RU2762359C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2017123551A 2014-12-05 2015-12-04 Химерные антигенные рецепторы, нацеленные на рецептор, связанный с g-белками, и их применение RU2762359C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462088286P 2014-12-05 2014-12-05
US62/088,286 2014-12-05
PCT/US2015/064102 WO2016090312A1 (en) 2014-12-05 2015-12-04 Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof

Publications (3)

Publication Number Publication Date
RU2017123551A RU2017123551A (ru) 2019-01-14
RU2017123551A3 true RU2017123551A3 (OSRAM) 2019-07-17
RU2762359C2 RU2762359C2 (ru) 2021-12-20

Family

ID=56092565

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017123551A RU2762359C2 (ru) 2014-12-05 2015-12-04 Химерные антигенные рецепторы, нацеленные на рецептор, связанный с g-белками, и их применение

Country Status (26)

Country Link
US (5) US10633426B2 (OSRAM)
EP (2) EP4015534A1 (OSRAM)
JP (4) JP6919091B2 (OSRAM)
KR (1) KR102612367B1 (OSRAM)
CN (4) CN113683711A (OSRAM)
AU (2) AU2015357518B2 (OSRAM)
CA (1) CA2969864A1 (OSRAM)
CY (1) CY1125008T1 (OSRAM)
DK (1) DK3227339T3 (OSRAM)
ES (1) ES2899779T3 (OSRAM)
HR (1) HRP20211978T1 (OSRAM)
HU (1) HUE057777T2 (OSRAM)
IL (2) IL310130A (OSRAM)
LT (1) LT3227339T (OSRAM)
MX (2) MX385156B (OSRAM)
MY (1) MY192065A (OSRAM)
PH (1) PH12017501044A1 (OSRAM)
PL (1) PL3227339T3 (OSRAM)
PT (1) PT3227339T (OSRAM)
RS (1) RS62870B1 (OSRAM)
RU (1) RU2762359C2 (OSRAM)
SA (1) SA517381665B1 (OSRAM)
SG (2) SG10202007326QA (OSRAM)
SI (1) SI3227339T1 (OSRAM)
SM (1) SMT202200040T1 (OSRAM)
WO (1) WO2016090312A1 (OSRAM)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113429484A (zh) * 2014-12-05 2021-09-24 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的抗体和使用方法
CN113683711A (zh) 2014-12-05 2021-11-23 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的嵌合抗原受体及其用途
IL303905A (en) 2015-05-18 2023-08-01 Tcr2 Therapeutics Inc Compositions and methods for TCR programming using fusion proteins
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
JP6925421B2 (ja) * 2016-08-05 2021-08-25 ワイ−バイオロジクス・インコーポレイテッド プログラム化された細胞死蛋白質リガンド−１（ｐｄ−ｌ１）に対する抗体及びその用途
ES2875959T3 (es) 2016-10-07 2021-11-11 Tcr2 Therapeutics Inc Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US12269859B2 (en) 2016-12-02 2025-04-08 Angeles Therapeutics, Inc. Synthetic immune receptors and methods of use thereof
AU2018205888B2 (en) 2017-01-05 2021-09-02 Kahr Medical Ltd. A PD1-41BBL fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
SI3565828T1 (sl) 2017-01-05 2022-04-29 Kahr Medical Ltd. SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo
SG11201907321TA (en) * 2017-02-07 2019-09-27 Daiichi Sankyo Co Ltd Anti-gprc5d antibody and molecule comprising the antibody
AU2018258045B2 (en) 2017-04-26 2024-02-29 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
ES2959953T3 (es) 2017-08-09 2024-02-29 Juno Therapeutics Inc Métodos para producir composiciones celulares genéticamente modificadas y composiciones relacionadas
MX2020001491A (es) 2017-08-09 2020-08-06 Juno Therapeutics Inc Metodos y composiciones para preparar celulas geneticamente modificadas.
EP3679370A1 (en) 2017-09-07 2020-07-15 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
EP3704229B1 (en) 2017-11-01 2023-12-20 Juno Therapeutics, Inc. Process for producing a t cell composition
SG11202003688PA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Process for generating therapeutic compositions of engineered cells
CN111655270A (zh) 2017-11-14 2020-09-11 纪念斯隆-凯特琳癌症中心 分泌il-36的免疫应答细胞及其用途
EP3716980A1 (en) 2017-12-01 2020-10-07 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
CA3084446A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
SG11202005228YA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Serum-free media formulation for culturing cells and methods of use thereof
KR102853341B1 (ko) 2017-12-08 2025-09-02 주노 쎄러퓨티크스 인코퍼레이티드 조작된 ｔ 세포의 조성물을 제조하는 방법
EP3774919A4 (en) * 2018-03-30 2021-12-29 Eureka Therapeutics, Inc. Constructs targeting cd22 and uses thereof
CA3100118A1 (en) 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
US12286466B2 (en) 2018-07-11 2025-04-29 Kahr Medical Ltd. PD1-4-1BBL variant fusion protein and methods of use thereof
KR20210059715A (ko) 2018-08-09 2021-05-25 주노 쎄러퓨티크스 인코퍼레이티드 통합된 핵산 평가 방법
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
JP7672340B2 (ja) * 2018-10-19 2025-05-07 メモリアル スローン ケタリング キャンサー センター シアリルルイスａを標的とするキメラ抗原受容体およびその使用
AU2019370705A1 (en) 2018-10-31 2021-05-27 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
PE20211058A1 (es) 2018-11-01 2021-06-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
CA3117419A1 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
WO2020113194A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
PH12021551676A1 (en) * 2019-01-18 2022-03-07 Janssen Biotech Inc Gprc5d chimeric antigen receptors and cells expressing the same
CN114025788A (zh) 2019-05-01 2022-02-08 朱诺治疗学股份有限公司 从经修饰的tgfbr2基因座表达重组受体的细胞、相关多核苷酸和方法
MX2021013223A (es) 2019-05-01 2022-02-17 Juno Therapeutics Inc Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
KR20220034782A (ko) 2019-06-12 2022-03-18 주노 쎄러퓨티크스 인코퍼레이티드 세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
US20220298222A1 (en) 2019-08-22 2022-09-22 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
AU2020377043A1 (en) 2019-10-30 2022-06-02 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4097218A1 (en) 2020-01-28 2022-12-07 Juno Therapeutics, Inc. Methods for t cell transduction
US11192940B2 (en) 2020-04-10 2021-12-07 Adagio Therapeutics, Inc. Compounds specific to coronavirus S protein and uses thereof
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
US20240216508A1 (en) 2020-06-26 2024-07-04 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
EP4240756A1 (en) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022148370A1 (en) * 2021-01-05 2022-07-14 Lanova Medicines Development Co., Ltd. Anti-gprc5d monoclonal antibodies and uses thereof
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
EP4308133A4 (en) 2021-03-17 2025-01-22 Myeloid Therapeutics, Inc. MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
AU2022244229A1 (en) 2021-03-22 2023-09-14 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
JP2024511418A (ja) 2021-03-22 2024-03-13 ジュノー セラピューティクス インコーポレイテッド 治療用細胞組成物の効力を決定する方法
WO2022216079A1 (ko) * 2021-04-07 2022-10-13 주식회사 엘지화학 Gucy2c 결합 폴리펩타이드 및 그의 용도
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
WO2022247756A1 (zh) * 2021-05-23 2022-12-01 上海邦耀生物科技有限公司 靶向gprc5d的嵌合抗原受体及其用途
US20240384001A1 (en) 2021-08-30 2024-11-21 Oricell Therapeutics Co., Ltd. Anti-gprc5d antigen binding protein and use thereof
KR20240099411A (ko) 2021-11-03 2024-06-28 얀센 바이오테크 인코포레이티드 항-cd38 항체를 사용한 치료에서 코르티코스테로이드 감소
CN118541399A (zh) 2022-01-14 2024-08-23 原启生物科技(上海)有限责任公司 靶向gprc5d的嵌合抗原受体及其用途
JP2025504002A (ja) 2022-01-28 2025-02-06 ジュノー セラピューティクス インコーポレイテッド 細胞組成物を製造する方法
US20250121064A1 (en) 2022-01-29 2025-04-17 Carsgen Life Sciences Co., Ltd Gprc5d antibody and use thereof
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
AU2023272490A1 (en) 2022-05-17 2024-12-12 Umoja Biopharma, Inc. Manufacturing viral particles
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
KR20250022800A (ko) 2022-06-10 2025-02-17 우모자 바이오파마 인코포레이티드 조작된 줄기 세포 및 그의 용도
WO2023250122A1 (en) * 2022-06-24 2023-12-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to enpp1 polypeptides
CA3259982A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
CN116003598B (zh) 2022-08-30 2024-04-26 苏州缔码生物科技有限公司 靶向人gprc5d的重组人源化单克隆抗体及其应用
JP2025531850A (ja) 2022-09-08 2025-09-25 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ
WO2024097992A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
EP4520346A1 (en) * 2023-09-06 2025-03-12 Gyncentrum Sp. z o.o. Cells, methods and systems for use in the treatment of a cancer with dual-car-t
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
CN120005019A (zh) * 2023-11-14 2025-05-16 成都优赛诺生物科技有限公司 一种靶向gprc5d的单域抗体、嵌合抗原受体及其应用
WO2025129084A1 (en) 2023-12-13 2025-06-19 Umoja Biopharma, Inc. Engineered induced stem cell derived myeloid cells and methods of differentiating and using same
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025231174A1 (en) 2024-04-30 2025-11-06 Umoja Biopharma, Inc. Manufacturing viral particles
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025231408A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025235604A1 (en) 2024-05-08 2025-11-13 Umoja Biopharma, Inc. Fusion protein for use as immune cell engager

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
KR20060088905A (ko) 2000-06-16 2006-08-07 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
WO2003016553A2 (en) 2001-08-20 2003-02-27 Genentech, Inc. Gpcr-like retinoic acid-induced gene 1 protein and nucleic acid
AU2002367145A1 (en) * 2001-12-27 2003-07-15 Sumitomo Pharmaceuticals Co., Ltd. Remedies for anorexia or lifestyle-related diseases and method of screening the same
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20040110139A1 (en) * 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of G protein-coupled receptor 3 expression
US7276372B2 (en) 2002-12-20 2007-10-02 Pdl Biopharma, Inc. Antibodies against GPR64 and uses thereof
EP1592713A2 (en) 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
SI2383295T1 (sl) * 2003-12-10 2015-07-31 E.R. Squibb & Sons, L.L.C. Protitelesa IP-10 in njihova uporaba
US20050266008A1 (en) * 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
JP5362563B2 (ja) 2006-08-03 2013-12-11 アストラゼネカ・アクチエボラーグ αＶβ６に対する抗体およびその使用
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
DK2856876T3 (en) 2007-03-30 2018-04-03 Memorial Sloan Kettering Cancer Center Constitutive expression of co-stimulatory ligands on adoptively transmitted T lymphocytes
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
US7947807B2 (en) 2007-10-15 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Method for obtaining G protein-coupled receptor (GPCR) diffraction-quality crystals employing a monoclonal antibody that binds to the third intracellular loop (IL3)
CN101808663B (zh) * 2007-10-25 2015-09-30 特雷利斯生物科学股份有限公司 抗rsv g蛋白抗体
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
AU2011282423B2 (en) 2010-07-22 2015-05-14 Schrader, Sabariah Cross-protective pathogen protection, methods and compositions thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013033626A2 (en) * 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
KR102064230B1 (ko) * 2013-02-15 2020-01-13 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
US9745368B2 (en) * 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2014273490B2 (en) * 2013-05-29 2019-05-09 Cellectis Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
SG11201609707WA (en) 2014-07-01 2017-01-27 Pfizer Bispecific heterodimeric diabodies and uses thereof
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
CN113429484A (zh) 2014-12-05 2021-09-24 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的抗体和使用方法
CN113683711A (zh) 2014-12-05 2021-11-23 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的嵌合抗原受体及其用途
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
WO2017096120A1 (en) 2015-12-04 2017-06-08 Memorial Sloan-Kettering Cancer Center Antibodies targeting fc receptor-like 5 and methods of use
KR20230148844A (ko) 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
CA3018253A1 (en) 2016-03-31 2017-10-05 University Of Southern California A highly sensitive and specific luciferase based reporter assay for antigen detection
CN112125976B (zh) 2018-01-26 2022-06-03 重庆精准生物技术有限公司 改造的铰链及其在构建car骨架中的应用
PE20211058A1 (es) 2018-11-01 2021-06-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)

Also Published As

Publication number Publication date
CN107428829B (zh) 2021-10-15
PH12017501044A1 (en) 2018-03-05
DK3227339T3 (da) 2022-01-10
AU2015357518B2 (en) 2021-10-07
US20180118803A1 (en) 2018-05-03
CY1125008T1 (el) 2022-07-22
MX2021008798A (es) 2021-08-24
MY192065A (en) 2022-07-25
US20200270328A1 (en) 2020-08-27
EP4015534A1 (en) 2022-06-22
JP2017537629A (ja) 2017-12-21
CN113968912A (zh) 2022-01-25
RS62870B1 (sr) 2022-02-28
JP2021040652A (ja) 2021-03-18
US20200270326A1 (en) 2020-08-27
CA2969864A1 (en) 2016-06-09
JP2025181929A (ja) 2025-12-11
SG10202007326QA (en) 2020-08-28
HUE057777T2 (hu) 2022-06-28
AU2022200052A1 (en) 2022-02-03
SA517381665B1 (ar) 2022-01-24
CN118271463A (zh) 2024-07-02
BR112017011920A2 (pt) 2018-02-27
MX385156B (es) 2025-03-14
IL310130A (en) 2024-03-01
WO2016090312A1 (en) 2016-06-09
JP2023091037A (ja) 2023-06-29
CN113683711A (zh) 2021-11-23
EP3227339B1 (en) 2021-11-10
NZ732574A (en) 2023-11-24
KR102612367B1 (ko) 2023-12-12
SMT202200040T1 (it) 2022-03-21
IL252621B2 (en) 2024-06-01
LT3227339T (lt) 2022-01-10
CN113968912B (zh) 2025-05-16
EP3227339A4 (en) 2018-08-08
US11820806B2 (en) 2023-11-21
EP3227339A1 (en) 2017-10-11
JP6919091B2 (ja) 2021-08-18
MX2017007242A (es) 2018-01-25
RU2762359C2 (ru) 2021-12-20
ES2899779T3 (es) 2022-03-14
SG11201704547RA (en) 2017-07-28
AU2015357518A1 (en) 2017-06-29
SI3227339T1 (sl) 2022-02-28
KR20170109537A (ko) 2017-09-29
IL252621B1 (en) 2024-02-01
RU2017123551A (ru) 2019-01-14
US10633426B2 (en) 2020-04-28
PT3227339T (pt) 2022-01-14
US20200270327A1 (en) 2020-08-27
CN107428829A (zh) 2017-12-01
US10906956B2 (en) 2021-02-02
PL3227339T3 (pl) 2022-02-21
IL252621A0 (en) 2017-07-31
US11866478B2 (en) 2024-01-09
HRP20211978T1 (hr) 2022-04-01
US20240294599A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
RU2017123551A3 (OSRAM)
BR112016017979A2 (OSRAM)
BR112016016225A2 (OSRAM)
BR112016016245A2 (OSRAM)
BR112016018948A2 (OSRAM)
BR112016016708A2 (OSRAM)
BR112016013761A2 (OSRAM)
BR112016018580A2 (OSRAM)
BR112016018369A2 (OSRAM)
BR112016016451A2 (OSRAM)
BR112016011585A2 (OSRAM)
BR112016019248A2 (OSRAM)
BR112016018564A2 (OSRAM)
BR112016015666A2 (OSRAM)
BR112016015243A2 (OSRAM)
BR112016016268A2 (OSRAM)
BR112016015542A2 (OSRAM)
BR112016015915A2 (OSRAM)
BR112016017681A2 (OSRAM)
BR112016000228A2 (OSRAM)
BR112016015911A2 (OSRAM)
BR112016019471A2 (OSRAM)
BR112016018896A2 (OSRAM)
BR112016004202A2 (OSRAM)
BR112016017717A2 (OSRAM)